カテゴリ： GlobalData, フランス, 企業調査

Sanofi (SAN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014241
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：441
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Sanofi is a healthcare company, which focuses on the research, development, manufacture and marketing a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The major products of the company include Aubagio, Lantus, Lovenox, Plavix and others. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 10
List of Figures 14
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 16
Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 17
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 18
Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 19
Sanofi, Medical Devices Deals, 2011 to YTD 2017 21
Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 22
Sanofi, Pharmaceuticals & Healthcare, Deal Details 36
Asset Purchase 36
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 36
Genzyme Acquires Caprelsa from AstraZeneca 38
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 39
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 40
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 41
Sanofi To Acquire Generic Drugs Rights From Medreich India 42
Aventis Pharma Acquires Nutraceutical Business From Universal Medicare For US$124 Million 43
Sanofi Aventis Plans To Acquire Generics And OTC Brands In India 44
Venture Financing 45
Thermalin Raises Funds through First Tranche of Series A Preferred Financing 45
Portal Instruments Raises USD25 Million in Series B Financing 46
MyoKardia Raises USD46 Million in Series B Financing 47
Portal Instruments Raises USD11 Million in Series A Venture Financing 48
Edimer Pharma Raises US$18 Million In Series B Financing 49
Ultragenyx Pharma Raises US$75 Million In Series B Financing 51
Kahr Medical To Raise US$2.5 Million In Venture Financing 53
Warp Drive Bio Raises US$75 Million In Series A Venture Financing 55
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 56
Esperance Pharma Secures US$7.5 Million In Series B Venture Financing 58
Fate Therapeutics Secures Venture Financing 60
Fate Therapeutics Raises US$36 Million In Series B Financing 62
Private Equity 64
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 64
Sanofi Plans to Sell Portfolio of Drugs 66
Partnerships 67
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 67
Berg Enters into Research Agreement with Sanofi 68
Applied BioMath Enters into Partnership with Sanofi 69
Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 70
Thermalin Enters into Partnership with Sanofi 71
Axxam Enters into Research Agreement with Sanofi 72
AbCellera Biologics Enters into Partnership with Sanofi Pasteur 73
Ex Scientia Enters into Research and Option Agreement with Sanofi 74
Sanofi Enters into Research Agreement with Exscientia 75
Sanofi Enters into Co-Development Agreement with MedImmune 76
Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 77
Enteris BioPharma Enters into Agreement with Sanofi 78
Sanofi Enters into Agreement with JHL Biotech 79
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 80
Mymetics Enters into Research Agreement with Sanofi 81
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 82
Myriad Enters into Agreement with Sanofi 83
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 84
Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 85
Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 86
Sanofi Enters into Research Agreement with Ksilink 87
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 88
Recursion Pharma Enters into Research Agreement with Genzyme 89
Hummingbird Bioscience Enters into Partnership with Sanofi 90
Sanofi Enters into Research Agreement with DiCE Molecules 91
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 92
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 93
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 95
X-Chem Enters into Agreement with Sanofi 96
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 97
Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 98
PeptiDream Enters into Discovery Agreement with Sanofi 99
Evotec Enters into Research Agreement with Sanofi 100
Regeneron Pharma Enters into Co-Development Agreement with Sanofi 101
Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 103
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 104
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 105
NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 106
Ablynx Enters into Research Agreement with Genzyme 107
Cystic Fibrosis Foundation Therapeutics Expands Research Agreement with Genzyme 108
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 109
VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 110
Schrodinger Enters into Agreement with Sanofi 111
Regeneron Pharma Amends Co-Development Agreement with Sanofi 112
Voyager Therapeutics Enters into Development Agreement with Genzyme 113
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 114
Sanofi Enters into Research Agreement with Vect-Horus 115
Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 116
Evotec to Enter into Co-Development Agreement with Sanofi 117
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 119
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 120
Apollo Hospitals Plans to Form Joint Venture with Sanofi 121
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 122
Genfit Amends Research Agreement with Sanofi 123
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 124
Sanofi Extends its Co-Development Agreement with MyoKardia 125
Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 127
Sanofi Enters into Co-Development Agreement with Medtronic 128
Sanofi Enters into Drug Discovery Agreement with CQDM 129
Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 130
Genzyme Enters Into Research Agreement With Cleveland Clinic 131
Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 132
Sanofi Enters Into Agreement With UCB For Drug Discovery 133
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 134
Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 136
Regulus Therapeutics Expands Agreement With Sanofi 137
Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 138
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 139
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 140
Sanofi Extends Research Agreement with Aviesan 141
Gubra Enters into Research Collaboration with Sanofi 142
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 143
NextBio Enters Into Agreement With Sanofi For Translational Medicine 144
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 145
Pieris And Sanofi Expand Agreement For Anticalin Therapeutics 146
Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 147
Oncodesign Enters Into Research Agreement With Sanofi 148
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 149
PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 150
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 151
Y-Biologics Expands Agreement with Sanofi 152
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 153
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 154
Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 155
China State Institute of Pharma Enters Into Research Agreement With Sanofi 156
Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 157
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 158
Sanofi Enters Into Research Agreement With Oncodesign 159
Sanofi Enters Into Research Agreement With Brigham and Women’s Hospital 160
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 161
Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 162
Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 163
Sanofi Enters Into Research Agreement With Bioneer 164
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 165
Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 166
Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 167
Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 168
Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 169
University of California Enters Into Research Agreement With Sanofi 170
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 171
Genzyme Enters Into Research Agreement With Cystic Fibrosis Foundation Therapeutics 172
CureVac Enters Into Co-Development Agreement With Sanofi Pasteur 173
Multicare Pharma Enters Into Co-Marketing Agreement With Sanofi 174
Valeant International Enters Into Distribution Agreement With Sanofi For Zuacta 175
Rib-X Pharma Signs Research Agreement With Sanofi 176
Sanofi Enters Into Research Agreement With Weill Cornell Medical College 177
Sanofi Enters Into Research Collaboration With Audion Therapeutics 178
Sanofi Enters Into Research Collaboration With DNDi 179
Alliance Pharma Extends Distribution Agreement With Sanofi Pasteur For ImmuCyst 180
Sanofi-aventis Enters Into Research Collaboration With Bio-X Stanford University 181
Sanofi-aventis Enters Into Research Collaboration With Columbia University 182
Genfit Enters Into Research Agreement With Sanofi-Aventis 183
ChemRar Enters Into Co-Development Agreement With Genzyme 184
AstraZeneca Enters Into Joint Venture With Sanofi, University Of Cambridge, EPFL, And Universities Of Pavia And Uppsala 185
Sanofi Pasteur Enters Into An Agreement With International Vaccine Institute 187
Sanofi-aventis Enters Into Research Agreement With Sunnybrook Health Sciences Center 188
UCSF Enters Into Co-Development Agreement With Sanofi-Aventis 189
Sanofi-Aventis Enters Into Research Agreement With UCSF 190
Merger 191
Sanofi Japan and Genzyme Japan Merge 191
Licensing Agreements 192
Sanofi to Enter into Licensing Agreement with Principia Biopharma 192
Sanofi Enters into Licensing Agreement with Ablynx 193
Sanofi Enters into Licensing Agreement with ImmuNext 194
Sanofi Enters into Licensing Agreement with Hanmi Pharma 195
IXALTIS Enters into Licensing Agreement with Sanofi 196
Mundipharma Enters into Licensing Agreement with SkyePharma for Flutiform in Mexico, Central and South America 197
Sanofi Enters into Licensing Agreement with Innate Pharma 198
Sanofi Amends Licensing Agreement with Lexicon Pharma 199
Zai Lab Enters into Licensing Agreement with Sanofi 200
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 201
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 202
Sanofi Pasteur Expands Licensing Agreement With Vivalis 203
Sanofi Enters into Licensing Agreement with Affilogic 204
Sanofi Enters into Licensing Agreement with Warp Drive Bio 205
Sanofi Enters into Licensing Agreement with MAB Discovery 206
Sanofi Enters into Licensing Agreement with BioNTech 207
Sanofi Enters into Licensing Agreement with Ligand Pharma 208
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 209
Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 210
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 211
Sanofi Enters into Licensing Agreement with Immune Design 212
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 213
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 214
Oxford BioMedica Amends Licensing Agreement With Sanofi 215
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 216
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 217
Regulus Therapeutics Enters Into Option For Licensing Agreement With Sanofi 218
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 219
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 220
Sanofi Exercises Option To License StarGen And UshStat From Oxford BioMedica 221
Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 222
Scil Technology Enters Into Licensing Agreement With Sanofi 223
Acton Pharma Enters Into Licensing Agreement With Sanofi-aventis For NASACORT HFA 224
Sanofi Pasteur Enters Into Licensing Agreement With University of California, San Diego 225
Sanofi Enters Into Licensing Agreement With Pfizer 226
SkyePharma Enters Into Licensing Agreement With Sanofi For Flutiform 227
Glenmark Pharma Enters Into Licensing Agreement With Sanofi For GBR 500 228
Oxford BioTherapeutics Enters Into Licensing Agreement With Sanofi 229
Equity Offering 230
JHL Biotech Raises USD80 Million in Private Placement of Shares 230
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 231
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 232
X4 Pharma Spin Off from Sanofi 233
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 234
KaloBios Pharma Completes IPO For US$70 Million 235
Debt Offering 237
Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 237
Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 238
Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 239
Sanofi Prices Public Offering of Notes Due 2019 for USD559 Million 240
Sanofi Prices Public Offering of Notes Due 2024 for USD670 Million 241
Sanofi Prices Public Offering of Notes Due 2028 for USD782 Million 242
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 243
Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 244
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 245
Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 246
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 247
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 248
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 249
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 250
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 251
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 253
Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 254
Sanofi Completes Public Offering Of Notes Due 2014 For US$750 Million 256
Sanofi Completes Public Offering Of 2.625% Notes Due 2016 For US$1,500 Million 258
Sanofi Completes Public Offering Of 4% Notes Due 2021 For US$2,000 Million 260
Sanofi Completes Public Offering Of 1.625% Notes Due 2014 For US$750 Million 262
Sanofi Completes Public Offering Of Notes Due 2012 For US$1,000 Million 264
Sanofi Completes Public Offering Of Notes Due 2013 For US$1,000 Million 266
Asset Transactions 268
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 268
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 270
Ipsen to Acquire Healthcare Portfolio from Sanofi for USD88.3 Million 271
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 273
Sanofi Plans to Sell its Generic Drug Business in Europe 274
Icagen Acquires Arizona Research Facility from Sanofi 275
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 276
Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 277
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 278
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 279
Ferring Pharma Acquires Ddavp from Sanofi 280
Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 281
Admedus Acquires Manufacturing Facility From Genzyme Australasia 282
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 283
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 284
Wood Pharma To Acquire Production Facility In Hlohovec From Zentiva 286
Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 287
Pierre Fabre Acquires Batrafen Shampooing Assets from Sanofi 288
Famar Completes Acquisition Of Madrid Facility From Sanofi 289
Hypermarcas Completes Acquisition Of Three Drug Brands From Medley Industria Farmaceutica 290
Genzyme Completes Sale Of Pharma Intermediates Business To International Chemical Investors 291
Biovail Labs Acquires Canadian Rights To Cholestagel From Genzyme 292
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 293
Acquisition 295
Sanofi Acquires Protein Sciences 295
Eurapharma Plans to Acquire 51% Stake in Maphar 296
Medis Labs Acquires Winthrop Pharma from Sanofi 297
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 298
Sanofi May Acquire BioMarin Pharma 299
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 300
Sanofi May Acquire PTC Therapeutics 301
Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 302
Dubai Investments Divests 66% Stake in Globalpharma 303
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 304
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 305
L’Oreal Plans To Sell Its Stake In Sanofi 306
Sanofi Plans To Acquire Consumer Healthcare Products Company In China 307
Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 308
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 309
Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 311
Evotec Acquires DeveloGen For USD18 Million 312
Valeant Pharma Completes Acquisition Of Dermik Labs From Sanofi 314
Sanofi Pasteur Acquires Topaz Pharma For Up To US$207.5 Million 316
Sanofi-Aventis Completes Acquisition Of Genzyme 317
Sanofi-Aventis Completes Acquisition Of BMP Sunstone 320
Deva Holding Acquires Zentiva Kimyasal Urnler 322
Sanofi – Key Competitors 323
Sanofi – Key Employees 324
Sanofi – Locations And Subsidiaries 326
Head Office 326
Other Locations & Subsidiaries 326
Joint Venture 339
Recent Developments 341
Strategy And Business Planning 341
May 05, 2016: Sanofi Sends Letter to Medivation’s Board 341
Apr 19, 2016: Sanofi Invests €300 Million To Expand Biologics Site in Belgium 342
Financial Announcements 343
Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 343
Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 350
Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 356
Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 358
Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 364
Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results 372
Jul 29, 2016: Sanofi Announces Q2 2016 Results 378
Jul 29, 2016: Royalty report for Q2 2016 and update on lixisenatide (Lyxumia/Adlyxin) and iGlarLixi 385
Apr 29, 2016: Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates 386
Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 392
Corporate Communications 399
Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 399
Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 400
Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 402
Sep 07, 2016: Sanofi Appoints New Research Head for Immunology and Inflammation 403
Sep 06, 2016: Sanofi Board Of Directors Provides Update 404
Jun 02, 2016: Sanofi India Announces Appointment of Chairman of the Board of Directors 405
Mar 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer 406
Legal and Regulatory 407
May 27, 2016: Medivation Files Preliminary Consent Revocation Statement 407
Government and Public Interest 409
Jun 13, 2016: Sanofi Files Definitive Consent Solicitation To Remove And Replace Medivation’s Board 409
Jun 01, 2016: Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation’s Board of Directors 410
May 05, 2016: NICE draft guidance recommends new drugs for cholesterol disorder 411
Feb 02, 2016: Even small improvements in blood glucose levels can result in huge benefits 412
Product News 413
12/02/2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491 413
10/26/2016: Flublok Influenza Vaccine Now Available in Mexico 414
10/11/2016: FDA Approves Flublok Quadrivalent Influenza Vaccine 415
09/20/2017: Sanofi and NIH researchers develop “three-in-one” antibodies as a potential breakthrough intervention for HIV/AIDS 416
09/11/2017: Sanofi Launches ‘Combiflam ICYHOT’ Pain Relief Topical in India 417
07/12/2016: 2016/17 Formulation of Flublok Influenza Vaccine Receives FDA Approval 418
06/30/2016: Flublok Influenza Vaccine is a great alternative for FluMist for adults 18 and older 419
06/22/2017: Superior Protection by Flublok Influenza Vaccine in Seniors Documented in New England Journal of Medicine 420
Jun 21, 2016: eClinicalHealth Announces Successful Results for an Entirely Remote Online Clinical Trial 421
06/17/2016: Hanmi Presented the Research Results of Efpeglenatide Long Acting Diabetes-Obesity Medicine at American Diabetes Association meeting 422
06/16/2017: Shantha Biotechnics’s Cholera Vaccine Completes Milestone of Delivering 10 Million Doses 423
05/25/2016: NICE recommends Jevtana (cabazitaxel) to treat eligible patients with advanced prostate cancer 424
04/22/2016: NICE recommends cabazitaxel for prostate cancer 425
04/19/2017: Peer Reviewed Publication Confirms the Absence of Rhabdovirus in Cell Line Used for Manufacturing of Flublok 426
04/04/2017: Flublok Quadrivalent Influenza Vaccine Adds a 9 Month Shelf Life to Its List of Benefits 427
02/03/2016: Connecticut lab working on Zika virus vaccine 428
Product Approvals 429
Aug 10, 2016: First Doses of Flublok Influenza Vaccine of 2016/17 Have Shipped 429
Jun 23, 2016: FDA Approved Longer Shelf Life for the Game Changer, Flublok Influenza Vaccine 430
Clinical Trials 431
Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491 431
Jan 12, 2017: Protein Sciences Zika Vaccine Shows Good Results in Preclinical Testing 432
Sep 28, 2016: Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development 433
Other Significant Developments 434
Mar 02, 2017: Sanofi Launches Digital Clinical Trials to Improve Recruitment and Reduce Trial Times 434
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 435
May 25, 2016: Sanofi Files Consent Solicitation To Remove and Replace Medivation’s Board 436
Apr 19, 2016: Sanofi Invests €300 Million To Expand Biologics Site in Belgium 439
Apr 19, 2016: Sanofi Invests €300 Million in its Biologics Site in Belgium to Develop its Monoclonal Antibodies Portfolio 440
Appendix 441
Methodology 441
About GlobalData 441
Contact Us 441
Disclaimer 441

List of Tables
Sanofi, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 16
Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 17
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 18
Sanofi, Deals By Therapy Area, 2011 to YTD 2017 19
Sanofi, Medical Devices Deals, 2011 to YTD 2017 21
Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 22
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 36
Genzyme Acquires Caprelsa from AstraZeneca 38
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 39
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 40
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 41
Sanofi To Acquire Generic Drugs Rights From Medreich India 42
Aventis Pharma Acquires Nutraceutical Business From Universal Medicare For US$124 Million 43
Sanofi Aventis Plans To Acquire Generics And OTC Brands In India 44
Thermalin Raises Funds through First Tranche of Series A Preferred Financing 45
Portal Instruments Raises USD25 Million in Series B Financing 46
MyoKardia Raises USD46 Million in Series B Financing 47
Portal Instruments Raises USD11 Million in Series A Venture Financing 48
Edimer Pharma Raises US$18 Million In Series B Financing 49
Ultragenyx Pharma Raises US$75 Million In Series B Financing 51
Kahr Medical To Raise US$2.5 Million In Venture Financing 53
Warp Drive Bio Raises US$75 Million In Series A Venture Financing 55
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 56
Esperance Pharma Secures US$7.5 Million In Series B Venture Financing 58
Fate Therapeutics Secures Venture Financing 60
Fate Therapeutics Raises US$36 Million In Series B Financing 62
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 64
Sanofi Plans to Sell Portfolio of Drugs 66
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 67
Berg Enters into Research Agreement with Sanofi 68
Applied BioMath Enters into Partnership with Sanofi 69
Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 70
Thermalin Enters into Partnership with Sanofi 71
Axxam Enters into Research Agreement with Sanofi 72
AbCellera Biologics Enters into Partnership with Sanofi Pasteur 73
Ex Scientia Enters into Research and Option Agreement with Sanofi 74
Sanofi Enters into Research Agreement with Exscientia 75
Sanofi Enters into Co-Development Agreement with MedImmune 76
Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 77
Enteris BioPharma Enters into Agreement with Sanofi 78
Sanofi Enters into Agreement with JHL Biotech 79
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 80
Mymetics Enters into Research Agreement with Sanofi 81
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 82
Myriad Enters into Agreement with Sanofi 83
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 84
Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 85
Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 86
Sanofi Enters into Research Agreement with Ksilink 87
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 88
Recursion Pharma Enters into Research Agreement with Genzyme 89
Hummingbird Bioscience Enters into Partnership with Sanofi 90
Sanofi Enters into Research Agreement with DiCE Molecules 91
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 92
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 93
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 95
X-Chem Enters into Agreement with Sanofi 96
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 97
Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 98
PeptiDream Enters into Discovery Agreement with Sanofi 99
Evotec Enters into Research Agreement with Sanofi 100
Regeneron Pharma Enters into Co-Development Agreement with Sanofi 101
Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 103
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 104
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 105
NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 106
Ablynx Enters into Research Agreement with Genzyme 107
Cystic Fibrosis Foundation Therapeutics Expands Research Agreement with Genzyme 108
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 109
VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 110
Schrodinger Enters into Agreement with Sanofi 111
Regeneron Pharma Amends Co-Development Agreement with Sanofi 112
Voyager Therapeutics Enters into Development Agreement with Genzyme 113
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 114
Sanofi Enters into Research Agreement with Vect-Horus 115
Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 116
Evotec to Enter into Co-Development Agreement with Sanofi 117
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 119
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 120
Apollo Hospitals Plans to Form Joint Venture with Sanofi 121
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 122
Genfit Amends Research Agreement with Sanofi 123
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 124
Sanofi Extends its Co-Development Agreement with MyoKardia 125
Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 127
Sanofi Enters into Co-Development Agreement with Medtronic 128
Sanofi Enters into Drug Discovery Agreement with CQDM 129
Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 130
Genzyme Enters Into Research Agreement With Cleveland Clinic 131
Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 132
Sanofi Enters Into Agreement With UCB For Drug Discovery 133
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 134
Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 136
Regulus Therapeutics Expands Agreement With Sanofi 137
Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 138
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 139
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 140
Sanofi Extends Research Agreement with Aviesan 141
Gubra Enters into Research Collaboration with Sanofi 142
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 143
NextBio Enters Into Agreement With Sanofi For Translational Medicine 144
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 145
Pieris And Sanofi Expand Agreement For Anticalin Therapeutics 146
Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 147
Oncodesign Enters Into Research Agreement With Sanofi 148
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 149
PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 150
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 151
Y-Biologics Expands Agreement with Sanofi 152
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 153
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 154
Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 155
China State Institute of Pharma Enters Into Research Agreement With Sanofi 156
Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 157
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 158
Sanofi Enters Into Research Agreement With Oncodesign 159
Sanofi Enters Into Research Agreement With Brigham and Women’s Hospital 160
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 161
Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 162
Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 163
Sanofi Enters Into Research Agreement With Bioneer 164
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 165
Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 166
Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 167
Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 168
Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 169
University of California Enters Into Research Agreement With Sanofi 170
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 171
Genzyme Enters Into Research Agreement With Cystic Fibrosis Foundation Therapeutics 172
CureVac Enters Into Co-Development Agreement With Sanofi Pasteur 173
Multicare Pharma Enters Into Co-Marketing Agreement With Sanofi 174
Valeant International Enters Into Distribution Agreement With Sanofi For Zuacta 175
Rib-X Pharma Signs Research Agreement With Sanofi 176
Sanofi Enters Into Research Agreement With Weill Cornell Medical College 177
Sanofi Enters Into Research Collaboration With Audion Therapeutics 178
Sanofi Enters Into Research Collaboration With DNDi 179
Alliance Pharma Extends Distribution Agreement With Sanofi Pasteur For ImmuCyst 180
Sanofi-aventis Enters Into Research Collaboration With Bio-X Stanford University 181
Sanofi-aventis Enters Into Research Collaboration With Columbia University 182
Genfit Enters Into Research Agreement With Sanofi-Aventis 183
ChemRar Enters Into Co-Development Agreement With Genzyme 184
AstraZeneca Enters Into Joint Venture With Sanofi, University Of Cambridge, EPFL, And Universities Of Pavia And Uppsala 185
Sanofi Pasteur Enters Into An Agreement With International Vaccine Institute 187
Sanofi-aventis Enters Into Research Agreement With Sunnybrook Health Sciences Center 188
UCSF Enters Into Co-Development Agreement With Sanofi-Aventis 189
Sanofi-Aventis Enters Into Research Agreement With UCSF 190
Sanofi Japan and Genzyme Japan Merge 191
Sanofi to Enter into Licensing Agreement with Principia Biopharma 192
Sanofi Enters into Licensing Agreement with Ablynx 193
Sanofi Enters into Licensing Agreement with ImmuNext 194
Sanofi Enters into Licensing Agreement with Hanmi Pharma 195
IXALTIS Enters into Licensing Agreement with Sanofi 196
Mundipharma Enters into Licensing Agreement with SkyePharma for Flutiform in Mexico, Central and South America 197
Sanofi Enters into Licensing Agreement with Innate Pharma 198
Sanofi Amends Licensing Agreement with Lexicon Pharma 199
Zai Lab Enters into Licensing Agreement with Sanofi 200
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 201
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 202
Sanofi Pasteur Expands Licensing Agreement With Vivalis 203
Sanofi Enters into Licensing Agreement with Affilogic 204
Sanofi Enters into Licensing Agreement with Warp Drive Bio 205
Sanofi Enters into Licensing Agreement with MAB Discovery 206
Sanofi Enters into Licensing Agreement with BioNTech 207
Sanofi Enters into Licensing Agreement with Ligand Pharma 208
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 209
Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 210
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 211
Sanofi Enters into Licensing Agreement with Immune Design 212
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 213
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 214
Oxford BioMedica Amends Licensing Agreement With Sanofi 215
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 216
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 217
Regulus Therapeutics Enters Into Option For Licensing Agreement With Sanofi 218
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 219
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 220
Sanofi Exercises Option To License StarGen And UshStat From Oxford BioMedica 221
Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 222
Scil Technology Enters Into Licensing Agreement With Sanofi 223
Acton Pharma Enters Into Licensing Agreement With Sanofi-aventis For NASACORT HFA 224
Sanofi Pasteur Enters Into Licensing Agreement With University of California, San Diego 225
Sanofi Enters Into Licensing Agreement With Pfizer 226
SkyePharma Enters Into Licensing Agreement With Sanofi For Flutiform 227
Glenmark Pharma Enters Into Licensing Agreement With Sanofi For GBR 500 228
Oxford BioTherapeutics Enters Into Licensing Agreement With Sanofi 229
JHL Biotech Raises USD80 Million in Private Placement of Shares 230
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 231
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 232
X4 Pharma Spin Off from Sanofi 233
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 234
KaloBios Pharma Completes IPO For US$70 Million 235
Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 237
Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 238
Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 239
Sanofi Prices Public Offering of Notes Due 2019 for USD559 Million 240
Sanofi Prices Public Offering of Notes Due 2024 for USD670 Million 241
Sanofi Prices Public Offering of Notes Due 2028 for USD782 Million 242
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 243
Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 244
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 245
Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 246
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 247
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 248
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 249
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 250
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 251
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 253
Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 254
Sanofi Completes Public Offering Of Notes Due 2014 For US$750 Million 256
Sanofi Completes Public Offering Of 2.625% Notes Due 2016 For US$1,500 Million 258
Sanofi Completes Public Offering Of 4% Notes Due 2021 For US$2,000 Million 260
Sanofi Completes Public Offering Of 1.625% Notes Due 2014 For US$750 Million 262
Sanofi Completes Public Offering Of Notes Due 2012 For US$1,000 Million 264
Sanofi Completes Public Offering Of Notes Due 2013 For US$1,000 Million 266
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 268
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 270
Ipsen to Acquire Healthcare Portfolio from Sanofi for USD88.3 Million 271
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 273
Sanofi Plans to Sell its Generic Drug Business in Europe 274
Icagen Acquires Arizona Research Facility from Sanofi 275
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 276
Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 277
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 278
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 279
Ferring Pharma Acquires Ddavp from Sanofi 280
Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 281
Admedus Acquires Manufacturing Facility From Genzyme Australasia 282
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 283
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 284
Wood Pharma To Acquire Production Facility In Hlohovec From Zentiva 286
Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 287
Pierre Fabre Acquires Batrafen Shampooing Assets from Sanofi 288
Famar Completes Acquisition Of Madrid Facility From Sanofi 289
Hypermarcas Completes Acquisition Of Three Drug Brands From Medley Industria Farmaceutica 290
Genzyme Completes Sale Of Pharma Intermediates Business To International Chemical Investors 291
Biovail Labs Acquires Canadian Rights To Cholestagel From Genzyme 292
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 293
Sanofi Acquires Protein Sciences 295
Eurapharma Plans to Acquire 51% Stake in Maphar 296
Medis Labs Acquires Winthrop Pharma from Sanofi 297
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 298
Sanofi May Acquire BioMarin Pharma 299
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 300
Sanofi May Acquire PTC Therapeutics 301
Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 302
Dubai Investments Divests 66% Stake in Globalpharma 303
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 304
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 305
L'Oreal Plans To Sell Its Stake In Sanofi 306
Sanofi Plans To Acquire Consumer Healthcare Products Company In China 307
Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 308
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 309
Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 311
Evotec Acquires DeveloGen For USD18 Million 312
Valeant Pharma Completes Acquisition Of Dermik Labs From Sanofi 314
Sanofi Pasteur Acquires Topaz Pharma For Up To US$207.5 Million 316
Sanofi-Aventis Completes Acquisition Of Genzyme 317
Sanofi-Aventis Completes Acquisition Of BMP Sunstone 320
Deva Holding Acquires Zentiva Kimyasal Urnler 322
Sanofi, Key Competitors 323
Sanofi, Key Employees 324
Sanofi, Subsidiaries 326
Sanofi, Joint Venture 339

★海外企業調査レポート[Sanofi (SAN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • IXYS, LLC：企業の戦略的SWOT分析
    IXYS, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • ProMIS Neurosciences Inc (PMN)-医療機器分野：企業M&A・提携分析
    Summary ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd. is a development stage biopharmaceutical company which focuses on the development of therapeutic antibodies and diagnostics for the treatment of misfolded protein diseases. The company uses ProMIS technology, which helps …
  • Orexigen Therapeutics Inc (OREX)-製薬・医療分野：企業M&A・提携分析
    Summary Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased …
  • Abreos Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Abreos Biosciences Inc (Abreos) is a biotechnology company with focus on the development of laboratory-based and point-of-care (POC) assays and reagents for the precision dose monitoring of biologic drugs. Its Monator, is a drug-monitoring test that provides physicians with vital information …
  • Tarsa Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Tarsa Therapeutics Inc (Tarsa) develops therapies for the treatment and prevention of osteoporosis and other bone related diseases. The company develops TBRIA, an oral formulation of calcitonin, a peptide hormone that inhibits bone resorption, which is used for the treatment of postmenopausa …
  • Larsen & Toubro Limited：企業の戦略・SWOT・財務情報
    Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report Summary Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Glidewell Laboratories：企業の戦略的SWOT分析
    Glidewell Laboratories - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • AltheaDx Inc：医療機器：M&Aディール及び事業提携情報
    Summary AltheaDx Inc (AltheaDx) is a molecular diagnostics company that offers development of pharmacogenetics. The company provides tests such as cardiovascular tests, pain tests, thrombophilia tests and psychiatric tests. It provides diagnostic development, clinical trial and discovery services. A …
  • Telkom SA SOC Limited：企業の戦略・SWOT・財務分析
    Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • BT Group plc：企業の戦略・SWOT・財務情報
    BT Group plc - Strategy, SWOT and Corporate Finance Report Summary BT Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Maruti Suzuki India Ltd (MARUTI)：企業の財務・戦略的SWOT分析
    Maruti Suzuki India Ltd (MARUTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Opthea Ltd (OPT)：企業の財務・戦略的SWOT分析
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vasc …
  • Jutal Offshore Oil Services Ltd (3303)：石油・ガス：M&Aディール及び事業提携情報
    Summary Jutal Offshore Oil Services Ltd (Jutal), a subsidiary of Cheung Hing Investments Ltd is an oil and gas company that offers oil and gas equipment and offshore engineering and technical supporting services. The company's products include natural gas processing systems, subsea equipment, produc …
  • Snam SpA (SRG)：石油・ガス：M&Aディール及び事業提携情報
    Summary Snam SpA (Snam) is an integrated midstream energy company. The company, through its subsidiaries, carries out the regasification, transportation, storage and supply of natural gas. It transports and dispatches natural gas through a transportation network, a dispatch center, supervisory distr …
  • Eloxx Pharmaceuticals Inc：企業のM&A・事業提携・投資動向
    Eloxx Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eloxx Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Nomura Holdings, Inc.：企業のM&A・事業提携・投資動向
    Nomura Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nomura Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Hitachi Construction Machinery Co., Ltd. (6305)：企業の財務・戦略的SWOT分析
    Hitachi Construction Machinery Co., Ltd. (6305) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • LIncoln Electric Holdings Inc：企業のM&A・事業提携・投資動向
    LIncoln Electric Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LIncoln Electric Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Zai Lab Ltd (ZLAB)：製薬・医療：M&Aディール及び事業提携情報
    Summary Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company’s pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It deve …
  • Midland Power Cooperative：発電所・企業SWOT分析
    Midland Power Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆